S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?

Hepion Pharmaceuticals (HEPA) Stock Price, News & Analysis

$2.75
+0.36 (+15.06%)
(As of 02/28/2024 ET)
Today's Range
$2.34
$2.82
50-Day Range
$1.51
$3.59
52-Week Range
$1.49
$20.66
Volume
105,463 shs
Average Volume
97,486 shs
Market Capitalization
$11.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Hepion Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.87mentions of Hepion Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($10.98) to ($11.43) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.60 out of 5 stars

Medical Sector

891st out of 958 stocks

Pharmaceutical Preparations Industry

389th out of 416 stocks

HEPA stock logo

About Hepion Pharmaceuticals Stock (NASDAQ:HEPA)

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

HEPA Stock Price History

HEPA Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Hepion Pharmaceuticals to Present at NASH-TAG 2024
Hepion Pharmaceuticals downgraded to Hold from Buy at Brookline
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Hepion Pharmaceuticals Announces Management Changes
See More Headlines
Receive HEPA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hepion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2020
Today
2/28/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:HEPA
Employees
25
Year Founded
2013

Profitability

Net Income
$-42,200,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$12.64 per share

Miscellaneous

Free Float
4,253,000
Market Cap
$11.94 million
Optionable
No Data
Beta
1.40

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. John T. Cavan (Age 66)
    Interim CEO & CFO
    Comp: $495.33k
  • Dr. Launa J. Aspeslet Ph.D.
    Chief Operating Officer
  • Sharen Pyatetskaya
    Director of Investor Relations
  • Dr. Daniel J. Trepanier Ph.D.
    Senior Vice President of Drug Development
  • Dr. Patrick R. Mayo Ph.D.
    Senior Vice President of Clinical Pharmacology
  • Dr. John Z. Sullivan-Bolyai (Age 76)
    Part-Time Consultant
  • Dr. Stephen A. Harrison FACP
    M.D., Scientific Advisory Board Chair & Consultant Medical Director














HEPA Stock Analysis - Frequently Asked Questions

Should I buy or sell Hepion Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hepion Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HEPA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HEPA, but not buy additional shares or sell existing shares.
View HEPA analyst ratings
or view top-rated stocks.

How have HEPA shares performed in 2024?

Hepion Pharmaceuticals' stock was trading at $3.24 at the beginning of the year. Since then, HEPA stock has decreased by 15.1% and is now trading at $2.75.
View the best growth stocks for 2024 here
.

Are investors shorting Hepion Pharmaceuticals?

Hepion Pharmaceuticals saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 79,100 shares, an increase of 18.2% from the January 31st total of 66,900 shares. Based on an average trading volume of 88,200 shares, the short-interest ratio is currently 0.9 days. Currently, 1.9% of the company's stock are sold short.
View Hepion Pharmaceuticals' Short Interest
.

When is Hepion Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our HEPA earnings forecast
.

How were Hepion Pharmaceuticals' earnings last quarter?

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) issued its quarterly earnings results on Sunday, November, 15th. The company reported ($13.80) EPS for the quarter, missing the consensus estimate of ($10.20) by $3.60.

When did Hepion Pharmaceuticals' stock split?

Shares of Hepion Pharmaceuticals reverse split on the morning of Thursday, May 11th 2023. The 1-20 reverse split was announced on Thursday, May 11th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Hepion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hepion Pharmaceuticals investors own include Bausch Health Companies (BHC), Axsome Therapeutics (AXSM), Archrock (AROC), Alector (ALEC), AIM ImmunoTech (AIM), Applied Genetic Technologies (AGTC), Abbott Laboratories (ABT) and Ambev (ABEV).

Who are Hepion Pharmaceuticals' major shareholders?

Hepion Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Armistice Capital LLC (9.63%), Vanguard Group Inc. (3.70%), Virtu Financial LLC (0.29%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Peter Wijngaard and Robert T Foster.
View institutional ownership trends
.

How do I buy shares of Hepion Pharmaceuticals?

Shares of HEPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HEPA) was last updated on 2/29/2024 by MarketBeat.com Staff

From Our Partners